header
Image from OpenLibrary

A pharmaceutical study on a colon targeted drug delivery system / Shaymaa Mohamed Elhady Ahmed ; Supervised Omaima Naim Elgazayerly , Manal Mohy Eldin Elashmoony , Mohamed Hassan Hany Kamel Hassan Aboughaly

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Shaymaa Mohamed Elhady Ahmed , 2020Description: 179 P. : charts , facsimiles ; 25cmOther title:
  • دراسة صيدلية على أحد الأنظمة الموجهة للقولون [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacrutics Summary: One of the challenges facing formulation scientists is the development of site specific delivery systems capable of releasing the active ingredient in the lower part of the small intestine and/or colon. Development of colon specific drug delivery systems can enhance the treatment of colonic conditions such as ulcerative colitis (UC), Crohn's disease (CD) and colorectal cancer (CRC). Colon targeted drug delivery systems (CTDDS)have the potential to reduce side effects and increase pharmacological response with low drug concentration. Recent studies proved the efficiency of celecoxib (CXB) for the treatment of inflammatory bowel diseases (IBD). CXB is a selective cyclooxygenase (COX)-2 inhibitor used as a non-steroidal anti-inflammatory drug with less gastrointestinal side effects compared to non-selective COX inhibitors. However, COX-2 inhibitors promote thrombosis and substantially increase the risk of heart attack at high doses after systemic administration.Being a Biopharmaceutical classification system (BCS) class II drug, it suffers from poor bioavailability (22-40%) caused by its low water solubility (3.3 æg/mL). Due to the colon low fluid volume, it will be more difficult to dissolve CXB in the colon
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.M.Sc.2020.Sh.P (Browse shelf(Opens below)) Not for loan 01010110081174000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.08.M.Sc.2020.Sh.P (Browse shelf(Opens below)) 81174.CD Not for loan 01020110081174000

Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacrutics

One of the challenges facing formulation scientists is the development of site specific delivery systems capable of releasing the active ingredient in the lower part of the small intestine and/or colon. Development of colon specific drug delivery systems can enhance the treatment of colonic conditions such as ulcerative colitis (UC), Crohn's disease (CD) and colorectal cancer (CRC). Colon targeted drug delivery systems (CTDDS)have the potential to reduce side effects and increase pharmacological response with low drug concentration. Recent studies proved the efficiency of celecoxib (CXB) for the treatment of inflammatory bowel diseases (IBD). CXB is a selective cyclooxygenase (COX)-2 inhibitor used as a non-steroidal anti-inflammatory drug with less gastrointestinal side effects compared to non-selective COX inhibitors. However, COX-2 inhibitors promote thrombosis and substantially increase the risk of heart attack at high doses after systemic administration.Being a Biopharmaceutical classification system (BCS) class II drug, it suffers from poor bioavailability (22-40%) caused by its low water solubility (3.3 æg/mL). Due to the colon low fluid volume, it will be more difficult to dissolve CXB in the colon

Issued also as CD

There are no comments on this title.

to post a comment.